Late endothelialization of first generation pharmacological stents may predispose thrombosis. Both the drug and the polymer of the platform may affect the rate at which this occurs. This is a prospective, multicenter study which randomized 44 patients with acute coronary syndrome to receive sirolimus-eluting stent with bio-absorbable polymer versus zotarolimus-eluting stent with permanent polymer. The<a href="https://solaci.org/en/2015/06/24/hattrick-oct-biodegradable-polymer-struts-coverage-versus-permanent/" title="Read more" >...</a>

This new stent is a sirolimus-eluting low-profile cobalt chrome platform (80 &micro;m) with a rapid resorption polymer (3 months). Theoretically, it presents less risk of inflammation of the vessel due to the kinetics of drug elution and polymer degradation. The objective of this study was to test the safety and efficacy of the new device.<a href="https://solaci.org/en/2015/06/24/century-new-clinical-results-of-sirolimus-eluting-degradable-polymer-stent/" title="Read more" >...</a>

There is still concern about the safety of drug-eluting stents (DES) due to the possibility of late and very late thrombosis. Dual antiplatelet aggregation for a year is recommended for patients receiving DES. The objective of this study was to test the non-inferiority of a new drug-eluting stent in terms of endothelial coverage after 3<a href="https://solaci.org/en/2015/06/24/demonstr8-better-endothelial-coverage-by-oct-for-the-new-des/" title="Read more" >...</a>

This non-inferiority design study compared the sirolimus-eluting stent with biodegradable polymer versus everolimus-eluting stent with permanent polymer in de novo coronary lesions. The primary endpoint was late lumen loss at nine months. We Included 440 patients with stable coronary lesions randomized 2:1 to receive the new sirolimus eluting stent with biodegradable polymer versus everolimus eluting<a href="https://solaci.org/en/2015/06/24/bioflow-ii-stent-eluidor-de-sirolimus-com-polimero-degradavel/" title="Read more" >...</a>

The HORIZONS AMI trial showed the usefulness of bivalirudin in reducing mortality and bleeding compared with the use of heparin plus glycoprotein IIBIIIA. However, some questions remained unanswered: What is the utility of starting the infusion during the ambulance journey? Is it possible to reduce the risk of acute thrombosis by extending bivalirudin infusion or<a href="https://solaci.org/en/2015/06/24/euromax-bivalirudin-during-transport-to-primary-angioplasty/" title="Read more" >...</a>

This new device consists of a novolimus releasing bioabsorbable polylactic acid platform that in vitro studies has shown equivalence to a Cypher stent. This device, also in vitro , showed a degradation time of one year and safety during post expansion, reaching 4.8 mm without fracturing. This is the first human trial and follow-up with<a href="https://solaci.org/en/2015/06/24/desolvenx-trial-results-of-the-new-bioabsorbable-platform/" title="Read more" >...</a>

Currently the recommendation is 12 months of dual antiplatelet after a drug-eluting stent angioplasty. This study compared the 3 &#8211; months versus 12 months of dual antiplatelet&nbsp; after angioplasty with zotarolimus-eluting stent in real-world patients. This was a prospective, multicenter study randomized 1563 patients to receive aspirin and clopidogrel for 3 months and 1556 to<a href="https://solaci.org/en/2015/06/24/optimize-3-versus-12-months-dual-antiplatelet-therapy-after-angioplasty-with-des/" title="Read more" >...</a>

This study randomized 1:1, &nbsp;906 patients to receive zotarolimus-eluting stent and 905 patients to receive everolimus-eluting stent. The clinical and angiographic characteristics of both groups were similar with approximately 45% of the population experiencing an acute coronary syndrome. There were no significant differences in major cardiac events between the two stents with 6.1% to for<a href="https://solaci.org/en/2015/06/24/dutch-peers-everolimus-des-versus-zotarolimus-des/" title="Read more" >...</a>

The aim of this study was to evaluate the clinical impact resistance thienopyridines through genetic analysis of CYP2C19 receptor. The primary endpoint was &nbsp;a combination of mortality, myocardial infarction, stent thrombosis in the resistance group (few responders) versus non-resistant (responders) to the thienopyridines. 1445 patients were included of which 22% were considered few responders. There<a href="https://solaci.org/en/2015/06/24/giant-evaluation-of-the-genetic-profile-of-cyp2c19-in-patients-undergoing-primary-angioplasty/" title="Read more" >...</a>

This study randomized 1259 patients to receive one year versus 2 years of double anti anti-platelet after implantation of a drug-eluting stent. The primary end point was a composite of death, myocardial infarction, stroke, stent thrombosis, and urgent revascularization that were equivalent between the two schemes. There was a trend to a higher rate of<a href="https://solaci.org/en/2015/06/24/arctic-interruption-1-years-versus-2-years-of-double-anti-platelet/" title="Read more" >...</a>